March 2, 2011
AURORA, Ontario, March 2, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced the issuance of a patent (U.S. Patent No. 7,872,105 B2) by the United States Patent & Trademark Office for the non-small cell lung cancer (“NSCLC”)-specific antibody component of its L-DOS47 drug candidate. As previously announced, the National Research Council of Canada (“NRC”) has granted Helix the right to use this antibody in combination with its DOS47 technology under a worldwide exclusive license agreement that extends to the full term of the applicable patents.